IP Library Granted Patent US 10,948,493
Granted Patent B2
US 10,948,493 · App. 15/782,804 · Granted Mar 16, 2021

Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a

Inventors: Fernando Jose Rebelo do Couto (Pleasanton, CA); Zhiming Liao (Livermore, CA); Yifei Zhu (San Jose, CA)
Assignee: Ventana Medical Systems, Inc.
G01N33/57492C07K16/28C07K16/30C07K2317/565C07K2317/567G01N1/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,948,493
App. No.
15/782,804
Granted
Mar 16, 2021
Kind
B2
Abstract

Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.

Claims (22)

1. A monoclonal C4.4a antibody specific for an epitope within a uPAR-like domain 2 within a human C4.4a protein, said monoclonal C4.4a antibody comprising a heavy chain variable region comprising heavy chain complementarity determining regions H-CDR1, H-CDR2, and H-CDR3, wherein H-CDR1 comprises SEQ ID NO: 23, H-CDR2 comprises SEQ ID NO: 25, and H-CDR3 comprises SEQ ID NO: 27, and further comprising a light chain variable region comprising light chain complementarity determining regions L-CDR1, L-CDR2, and L-CDR3, wherein L-CDR1 comprises SEQ ID NO: 31, L-CDR2 comprises SEQ ID NO: 33, and L-CDR3 comprises SEQ ID NO: 35.

2. The monoclonal C4.4a antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 17.

3. The monoclonal C4.4a antibody of claim 1 , wherein the uPAR like domain 2 comprises SEQ ID NO: 4.

4. The monoclonal C4.4a antibody of claim 1 , wherein the heavy chain variable region further comprises heavy chain framework regions H-FR1, H-FR2, H-FR3, and H-FR4, wherein H-FR1 comprises SEQ ID NO: 22, H-FR2 comprises SEQ ID NO: 24, H-FR3 comprises SEQ ID NO: 26, and H-FR4 comprises SEQ ID NO: 28.

5. The monoclonal C4.4a antibody of claim 1 , wherein the light chain variable region further comprises light chain framework regions L-FR1, L-FR2, L-FR3, and L-FR4, wherein L-FR1 comprises SEQ ID NO: 30, L-FR2 comprises SEQ ID NO: 32, L-FR3 comprises SEQ ID NO: 34, and L-FR4 comprises SEQ ID NO: 36.

6. The monoclonal C4.4a antibody of claim 1 , wherein the light chain variable region comprises SEQ ID NO: 18.

7. The monoclonal C4.4a antibody of claim 2 , wherein the light chain variable region comprises SEQ ID NO: 18.

8. A kit comprising a C4.4a antibody according to claim 1 .

9. The kit of claim 8 , wherein the monoclonal C4.4a antibody is adapted for immunohistochemistry.

10. The kit of claim 8 further comprising a detection system for making the C4.4a antibody visible.

11. The kit of claim 10 , wherein the detection system comprises a chromogenic detection system.

12. The kit of claim 10 , wherein the detection system comprises a fluorescence detection system.

13. A method of labeling a biological sample for human C4.4a protein, said method comprising:

a. contacting a sample with a C4.4a antibody according to claim 1 ; and

b. making the antibody bound to the sample visible.

14. The method of claim 13 , wherein the biological sample is a tissue sample.

15. The method of claim 14 , wherein the tissue sample is a formalin fixed, paraffin embedded (FFPE) tissue sample.

16. The method of claim 13 , wherein the step of making the antibody visible comprises contacting the antibody with a chromogenic detection system or a fluorescence detection system.

17. The method of claim 13 , wherein the biological sample is from a human.

18. The method of claim 17 , wherein the biological sample is a tissue sample.

19. The method of claim 18 , wherein the tissue sample is a formalin fixed, paraffin embedded (FFPE) tissue sample of a human tumor.

20. A method of diagnosing a C4.4a-associated tumor, said method comprising obtaining a tumor sample, labeling the tumor sample for human C4.4a protein according to the method of claim 13 , and detecting the presence or absence of visible antibody, wherein detection of visible C4.4a antibody is indicative that the tumor is the C4.4a-associated tumor.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: COUTO, FERNANDO JOSE REBELO DO; LIAO, ZHIMING; ZHU, YIFEI
To: SPRING BIOSCIENCE CORPORATION
Reel/Frame 055104/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: SPRING BIOSCIENCE CORPORATION
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 055104/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: SPRING BIOSCIENCE CORPORATION
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 052932/0937 →
Continuity (3)
Continuation PCTEP2016058135 · Apr 13, 2016
Provisional Application 62149239 · Apr 17, 2015
Related Publication 20180031566A1 · Feb 1, 2018